Biotech VC Funds

Morpheus Ventures, founded in 2016 and based in Los Angeles, focuses on early-stage investments in cutting-edge technologies such as data analytics, machine learning, robotics, and SaaS. Their portfolio includes innovative companies like Rigetti Computing, Vicarious, and Starship Technologies. The firm has made significant exits including Rigetti Computing and Vicarious (acquired by Alphabet). Other notable investments include HouseCanary, a real estate data analytics company, SafetyCulture, a leading safety and quality inspection software, and Sidecar Health, a health insurance platform. The leadership team at Morpheus Ventures includes experienced investors like Damien Petty, who has a background in artificial intelligence, robotics, and quantum computing, and has led investments in companies like DeepMind (acquired by Google) and Skype (acquired by Microsoft). The team focuses on identifying and nurturing companies with the potential to disrupt their respective industries and drive significant advancements in technology.

Mosaic Venture Lab (MVL) is a Taiwan-based corporate-innovation platform and early-stage venture investor founded in 2018 and headquartered in Taipei, with on-the-ground experience spanning Taiwan, Japan, and Korea. The organization is powered by three strategic corporate backers — Audi AG, Continental AG, and Taiwanese electronics giant LITEON — and exists to bridge global automotive and industrial leaders with East Asia's advanced manufacturing and technology ecosystems. MVL has raised a dedicated approximately $100 million fund aimed at EV and mobility opportunities in Taiwan. MVL's thesis is AI-driven transformation: identifying, assessing, and integrating disruptive AI and deep-tech solutions for multinational automotive and industrial partners, with strong concentration in automotive and mobility (electric, autonomous, and connected vehicles), healthcare, and semiconductors. The firm operates as a hybrid — part corporate accelerator, part early-stage investor, part product-development and scouting agency — and has helped portfolio companies raise over USD 100 million in aggregate while brokering commercial partnerships with Audi, BMW, Continental, and Volkswagen. Over its active history MVL has made 17 investments. Notable portfolio companies include Jmem-Tek (Taiwan, semiconductor hardware-security IP), PackAge+ (Taiwan, sustainable circular packaging demonstrated at LITEON's Kaohsiung factory), and Elephantech (Japan, sustainable low-carbon PCB materials and processes, with mass production planned for 2025 in partnership with LITEON). The most recent disclosed investment was in Taiwan Universe BioMedicine in August 2025. MVL's differentiation lies in its ability to shorten the gap between a startup's technical proof of concept and a commercial partnership with a top-tier automotive or electronics OEM — converting pilot discussions that typically take years into structured engagement within months.

MTN Group is a leading telecommunications company based in Johannesburg, South Africa. The company has a strong presence across Africa and the Middle East, serving over 289 million subscribers. MTN Group's investment arm has made notable investments in sectors such as telecom infrastructure, renewable energy technology, and horizontal e-commerce. Key investments include companies like Fenix International, a renewable energy company acquired by ENGIE, and Jumia, a leading e-commerce platform in Africa. Another significant investment is in IHS Towers, one of the largest independent owners, operators, and developers of shared telecommunications infrastructure. MTN Group has committed substantial funds towards infrastructure projects to enhance its service delivery. For instance, it pledged $215 million for infrastructure investment in Benin over three years, focusing on building a state-of-the-art office for MTN Benin and expanding digital solutions across the region. Financially, MTN Group has reported strong performance with a 23.4% return on equity and a 10% increase in dividends to 330 cents per share. The group's strategic focus includes expanding its fintech ecosystem, investing in network infrastructure, and promoting digital inclusion across its markets.

Moving Capital, now known as Karman Ventures, is a venture capital firm founded by Uber alumni to support startups with innovative solutions. The firm has made notable investments across various sectors, including aerospace, artificial intelligence, retail technology, and green technology. Noteworthy investments by Karman Ventures include Whisper Aero, a company focusing on aerospace and green technology; Luca, which specializes in AI-driven retail technology; and Regent, which develops electric vehicles for marine transportation. Other significant investments are in companies like Gigs, focusing on mobile applications, and Kasa Living, a hospitality tech company. Karman Ventures is based in Austin, Texas, and has a strong network of co-investors, including prominent firms like Y Combinator, Menlo Ventures, and LaunchTN. Their investment strategy typically involves supporting companies from seed to growth stages, emphasizing scalable and transformative technologies.

Moxxie Ventures is a venture capital firm founded in 2019 by Katie Jacobs Stanton, a former Twitter executive and co-founder of the #ANGELS investment collective. The firm is based in Mountain View, California, with a secondary office in Boulder, Colorado. Moxxie Ventures focuses on early-stage investments, particularly in consumer, enterprise, fintech, healthtech, and climate sectors. Moxxie Ventures recently closed its second fund at $85 million, a significant increase from its inaugural $25 million fund. The firm typically writes checks ranging from $250,000 to $500,000 and aims to make 10 to 12 investments per year, reserving half of the fund for follow-on investments. Notable investors backing Moxxie Ventures include Bain Capital Ventures, Bloomberg Beta, Foundry Group, and individual investors such as Marc Andreessen, Susan Wojcicki, and Jerry Yang. The firm prides itself on bringing a combination of capital, operating experience, and a strong network to its portfolio companies. Stanton and her team leverage their extensive backgrounds in product, engineering, marketing, and business development to support founders in scaling their businesses. Moxxie Ventures is committed to partnering with founders who are passionate about making life and work better through innovative solutions. Some of their notable investments include companies like Elpha, Carta, and Clubhouse. The firm continues to build on its mission to support founders with not just funding but also strategic guidance and connections to a broad network of industry experts and leaders.

MPM Capital, founded in 1997, is a leading venture capital firm based in Boston and San Francisco, specializing in biotechnology and life sciences investments. The firm has a robust portfolio, having invested in over 150 companies, including notable names like 23andMe, ReNAgade Therapeutics, and Argenx. MPM Capital's focus is on transforming innovative scientific discoveries into breakthrough medicines, particularly in oncology and other high-need therapeutic areas​. MPM Capital recently raised $850 million for its second Oncology Impact Fund, marking it as one of the largest biotech impact investment funds globally. This fund emphasizes investments in companies developing novel cancer therapies, reflecting MPM's deep commitment to addressing significant medical challenges. The firm's team includes seasoned professionals with extensive experience in research, drug development, and corporate strategy. Key team members like Dr. Luke Evnin and Dr. Ansbert Gadicke bring invaluable expertise to the firm, guiding its strategic investments and supporting portfolio companies through various growth stages​ .

Mubadala Capital’s Ventures platform stands out as a leading global investor, blending the strengths of Mubadala Investment Company with the agility of a venture capital firm. Focused on technology and healthcare sectors, Mubadala has made over 75 investments, including notable startups like Chroma Medicine, Recursion Pharmaceuticals, and Exscientia. Their strategy revolves around partnering with visionary founders to build enduring companies, leveraging Mubadala’s extensive resources and global scale. Geographically, Mubadala Ventures operates with a significant presence in technology hubs such as San Francisco, London, and Abu Dhabi, ensuring deep integration into the global innovation ecosystem. They emphasize Series A+ investments in the U.S. and Series B+ in Europe, providing substantial capital and strategic support to their portfolio companies. Mubadala's investment strategy is marked by a focus on capital preservation and downside protection, ensuring sustainable growth and returns. The fund typically invests in founder-led companies, with average check sizes tailored to the needs of each growth stage. They are known for their disciplined approach to evaluating opportunities, benefiting from Mubadala's broad network and sovereign backing. The team at Mubadala Ventures includes industry veterans like Ibrahim Ajami, Head of Ventures, and Alaa Halawa, Co-Head of US Ventures. Their expertise spans various sectors and geographies, further strengthening Mubadala’s investment acumen. Startups looking to engage with Mubadala are advised to highlight their alignment with Mubadala’s strategic focus and demonstrate robust business models that can benefit from Mubadala’s vast resources and network.

Mucker Capital, founded in 2012 and headquartered in Los Angeles, is a venture capital firm that invests in seed and early-stage startups across the United States, Canada, and beyond. With additional offices in Austin and Toronto, Mucker Capital focuses on internet-enabled software and services, aiming to support startups outside the traditional Silicon Valley ecosystem. The firm believes that great companies can be built anywhere and provides tactical help, networking opportunities, and a bridge to Silicon Valley resources. Notable portfolio companies include Honey, acquired by PayPal; Surf Air, which went public on NASDAQ; and ServiceTitan, a business management software for home service providers. Mucker Capital has also backed companies like The Black Tux, ServiceTitan, and BloomNation. MuckerLab, their pre-seed accelerator, is highly regarded and ranked second in the U.S. by the Seed Accelerator Rankings Project based on valuations, exits, fundraising, survival, and founder satisfaction. Mucker Capital's approach includes rolling up their sleeves to work alongside entrepreneurs on product development, marketing, sales, recruiting, and other critical areas to help startups succeed. The firm has launched multiple funds, including Mucker III, a $45 million seed-stage fund, and continues to support the growth and scaling of innovative startups.

Muse Capital is an early-stage venture capital fund based in Los Angeles, California, focused on investing in consumer-facing startups. Founded in 2016, the firm aims to bridge the gap between Silicon Valley, the entertainment industry, and the corporate sector, providing strategic capital and partnership-based business development. Muse Capital has a diverse portfolio that includes companies like CoFertility, Beekeeper's Naturals, Cloud Paper, and Firefly, all of which are pushing boundaries in telehealth, education, motherhood, gaming, and underserved markets. The firm is led by Assia Grazioli-Venier and Rachel Springate, who leverage their extensive networks in the entertainment and corporate worlds to support their portfolio companies. Muse Capital typically invests in seed-stage rounds, providing both financial backing and strategic guidance to help startups grow and succeed. Muse Capital is particularly known for its active involvement in the companies it invests in, offering tactical insights and connections to key industry players. This hands-on approach has made Muse a valuable partner for entrepreneurs looking to disrupt and innovate within the consumer sector. For startups looking to engage with Muse Capital, demonstrating a clear vision for consumer impact and leveraging the firm’s entertainment and corporate connections can be crucial.

MVM Partners, founded in 1997, is a global venture capital firm focused on high-growth healthcare investments. With offices in Boston and London, MVM invests broadly across sectors including medical technology, pharmaceuticals, diagnostics, digital health, and other healthcare-related fields. Their portfolio includes notable companies such as SkyCell, which developed patented temperature-control technology for safely transporting vaccines and biotech drugs, and Ossio, which created OSSIOfiber Intelligent Bone Regeneration Technology—a novel orthopedic fixation material that integrates into native bone and avoids the need for permanent metal implants. MVM also invested in MDxHealth, a company specializing in molecular diagnostics for urologic cancers, which enhances personalized cancer diagnosis and treatment. MVM's investment strategy emphasizes significant minority stakes in innovative companies, providing both financial support and strategic guidance to help these companies grow and scale. Their approach involves close collaboration with management teams to drive business development and market expansion. MVM's recent investments include companies like eXmoor Pharma, which focuses on cell and gene therapy services, and Nalu Medical, which develops minimally invasive solutions for chronic pain management. These investments reflect MVM's commitment to supporting advancements in medical technology and improving patient outcomes globally.

My Climate Journey Collective (MCJ Collective) is a venture capital firm dedicated to investing in innovative climate solutions. Founded to drive significant impact in combating climate change, MCJ Collective supports early-stage startups across a range of sectors including renewable energy, mobility, food systems, and sustainable infrastructure. MCJ Collective's portfolio includes notable companies such as BlocPower, which focuses on clean energy and smart city solutions, and Arcadia, a technology company democratizing access to clean energy. They have also invested in Enode, a developer of APIs for information services, and Hoxton Farms, a biotechnology company working on sustainable food solutions. The firm is known for its broad investment strategy, backing startups that aim to mitigate climate change and improve environmental sustainability. They have a strong focus on sectors like renewable energy, electrification, carbon management, and the built environment. MCJ Collective emphasizes the importance of technological innovation in addressing climate challenges, supporting companies that leverage AI, data centers, and other advanced technologies. The team at MCJ Collective includes experienced professionals with a deep understanding of climate issues and investment strategies, ensuring that they provide not only capital but also strategic guidance to their portfolio companies. For more detailed information, you can explore their portfolio and insights on their official.

Myelin VC is a venture capital firm founded in 2019 with operations across Madrid, Spain, Montevideo, Uruguay, and Buenos Aires, Argentina. The fund's name references the myelin sheath that accelerates neural signals, and its mission centers on backing startups whose ideas reshape how people think, collaborate, and solve problems at scale. Myelin is a $50 million fund that takes an industry-agnostic approach to early-stage technology, writing checks of $250,000 to $1 million from seed through Series A. The team is led by General Partners Matias Nisenson (blockchain gaming and DeFi background), Martin Varsavsky (telecom and fertility entrepreneur), Cesar Levene, and Non-Executive General Partner Alec Oxenford (founder of OLX), with Investment Partner Federico Jack also involved in deal execution. As of November 2024 Myelin had invested in 42 companies spanning healthtech, biotech, food and beverage, SaaS, fintech, AI, and web3. Notable portfolio companies include CookUnity, a rapidly scaling food-tech platform; Daye, a women's health company founded by Valentina Milanova; Aura Biosciences, founded by Elisabeth de Los Pinos (an exit); Buenbit, a fintech founded by Federico Ogue; Pipedream Labs ($13 million round in 2024 alongside Starship Ventures and Cortado Ventures); NUE Life Health (an exit); Nodal ($4 million seed extension, November 2024); Throne (gut-health AI, May 2025); and Midas Software (most recent investment, March 2026). Three companies have exited to date. Myelin's tri-city presence across Madrid, Montevideo, and Buenos Aires anchors it as a genuinely transatlantic fund, with the ability to source from Spain's growing startup ecosystem and Latin America's deep pool of technical and commercial talent simultaneously.

Mystic Ventures, founded in 2021 and based in Los Angeles, is a venture capital firm focused on the rapidly growing psychedelic medicine and mental health sector. The fund is committed to advancing research and developing innovative treatments using psychedelics to address conditions like depression, anxiety, PTSD, and other mental health issues. Mystic Ventures typically invests in pre-seed and seed-stage companies that are pioneering these therapies. Led by Jeremy Gardner and Brock Pierce, the firm takes a biotech-oriented approach, partnering with scientific research teams and pharmaceutical experts to bring cost-effective, holistic psychedelic solutions to the mainstream. With a rolling fund structure on AngelList, Mystic Ventures is uniquely positioned to offer flexible capital to startups, supporting their long-term growth in the burgeoning field of psychedelic therapeutics. The fund has backed companies like Psylo and Heading Health, among others. By investing in breakthrough treatments that go beyond traditional pharmaceutical approaches, Mystic Ventures aims to reshape how mental health treatments are developed and accessed, while offering investors exposure to this transformative market.

N49P Ventures, established in 2019 and headquartered in Toronto, Canada, focuses on seed-stage investments in Canadian technology startups. The firm primarily invests in sectors such as e-commerce, AI, fintech, and software, supporting companies with their growth and market expansion strategies. Notable portfolio companies include Visualping, which raised $6 million for its website change monitoring service, and Rally, a software company that secured $10 million in funding. N49P has also backed startups like Spellbook and EvenUp, both of which operate in the legal AI space​. The team at N49P includes founders Doug Penick, Alex Norman, and Omar Dhalla, all of whom bring extensive experience in investment and operational roles. They are actively involved in supporting their portfolio companies through fundraising, customer introductions, and ongoing coaching. N49P emphasizes building a strong community of investors who are dedicated to supporting the Canadian tech ecosystem. This community includes active founders, business executives, and exited teams who contribute their expertise and networks to help portfolio companies succeed​.

Nameless Ventures is a Chicago-based venture capital firm founded in 2017. Focused on early-stage investments, the firm actively seeks out opportunities across high-tech, enterprise software, and consumer-focused sectors. Its portfolio includes 17 companies, with notable investments in Kin, a rapidly growing insurtech unicorn, as well as PechaKucha and Nutrisense. While it has yet to make new investments in 2024, Nameless Ventures has backed ventures in sectors such as media services, healthcare, and fintech. The firm predominantly invests in the U.S., with a small footprint in Canada. Its strategy centers on seed and Series A rounds, with a preference for high-potential startups at early stages of revenue generation. Despite an average check size ranging between $2 million and $5 million, Nameless Ventures doesn’t always lead investment rounds, often partnering with co-investors like Techstars and QED Investors. Led by industry veterans Tom Firestine, Pavel Sokolovsky, and Erik Hubbard, Nameless Ventures provides a hands-on approach to its portfolio companies, leveraging expertise in marketing, product design, and supply chain management. The team is small but experienced, drawing from backgrounds in scaling consumer brands and cutting-edge tech solutions. Founders looking to connect should aim for a direct approach, highlighting strong product-market fit and scalability potential​.

Navigare Ventures, founded in 2021 and based in Stockholm, is an early-stage venture capital firm specializing in science-driven companies. As a subsidiary of Wallenberg Investments AB, Navigare Ventures focuses on deep tech sectors, including advanced computing, quantum technologies, synthetic biology, bio innovation, and data-driven life sciences. The firm is committed to investing in transformative technologies that have a strong industrial and societal impact. Navigare Ventures typically invests in Seed and Series A rounds, partnering closely with founders to support the growth and development of their companies. The firm has a robust portfolio that includes companies like Elypta, a startup developing metabolism-based liquid biopsy technology for cancer detection, and EnginZyme, which focuses on sustainable biomanufacturing. Their investment strategy is characterized by long-term partnerships, leveraging an extensive network of scientific and industrial expertise to help startups scale and succeed in their respective fields​.

NCL Technology Ventures is a UK-based venture capital firm specializing in early-stage investments across the healthcare and life sciences sectors. Founded in 2010, the firm focuses on identifying and backing companies that are driving transformational change in healthcare, with a particular emphasis on innovation in areas such as therapeutics, medical technologies, and digital health. NCL's mission is to foster companies that are developing breakthrough solutions to address global health challenges, from preventive care to cutting-edge treatments​. The firm's investments typically range between €1.5M and €3M, with a strong focus on seed and Series A funding. NCL is deeply involved in the strategic development of its portfolio companies, providing both capital and operational expertise to help them navigate the complexities of the healthcare landscape. The firm's portfolio includes companies like TC BioPharm, which is pioneering allogeneic cell therapies, and Curesponse, a precision medicine startup. With offices in London and the US, NCL is well-positioned to support its portfolio globally, fostering partnerships and driving innovation in both European and American markets. Their team, led by experienced venture capitalists like Jerry Biggs and Jonathan Synett, brings decades of investment and entrepreneurial expertise to the table.

NCore Ventures is a Seoul, South Korea-based venture capital firm founded in 2017 that focuses on mid- to late-stage technology investments across the United States and Asia. Led by CEO Ryan Park and CFO Jean Yang, the firm operates with a lean team of four and invests primarily at Series A and Series B across Indonesia, Japan, Singapore, South Korea, the United States, and Vietnam. Sector coverage spans consumer, enterprise applications, healthtech, and other high-growth technology categories. NCore has made 43 investments and built a portfolio with an outsized return profile: 7 unicorns, 4 IPOs, and 1 acquisition to date. Notable portfolio companies include Blinkit, the Indian quick-commerce platform acquired by Zomato in June 2022 for $568 million; GrubMarket, a US online grocery and food supply-chain platform; Carro, a Southeast Asian automotive marketplace; Lunit, an AI medical imaging company listed on the Korea Exchange at a market capitalization of $241 million; and Xcell Therapeutics, which listed on KRX in July 2024 at a $78.2 million market cap. More recent additions include Btree, an electronic instruments company in which NCore invested in November 2024, and Galux, a Series B investment made in February 2026. NCore's investment thesis is centered on identifying companies at the inflection point between early-stage validation and meaningful scale, where the firm's regional network across Asia and the United States provides a distinct advantage in both deal sourcing and portfolio support. Its track record of backing multiple unicorns across diverse geographies underscores the breadth of its analytical lens.

Necessary Ventures is a San Francisco-based venture capital firm focused on investing in early-stage companies that address significant societal needs. The firm is led by Neil Devani, who brings extensive experience in both venture capital and entrepreneurship. Necessary Ventures primarily invests in companies across a range of sectors including health tech, financial services, biotechnology, and sustainability. Notable investments in their portfolio include Recursion Pharmaceuticals, a company revolutionizing drug discovery through advanced computational methods; Rubi Laboratories, which converts CO2 into sustainable textiles; and Andela, a tech talent training and employment platform. Additionally, they have backed Vicarious Surgical, which develops minimally invasive robotic surgery technology, and Wayve, an AI-driven autonomous vehicle company. The firm is known for its hands-on approach, providing not just capital but also strategic guidance and support to help their portfolio companies scale and succeed. They emphasize a collaborative and empathetic partnership with founders, aiming to create long-term value and impact. Necessary Ventures has a strong presence in both the U.S. and international markets, with investments in various high-growth regions. They have co-invested with leading venture funds such as Y Combinator, Collaborative Fund, and Talis Capital, highlighting their integration into a robust network of investors.

Neo is a venture capital firm based in San Francisco, founded by Ali Partovi, with a strong emphasis on supporting the next generation of tech leaders. Launched in 2012, Neo invests primarily in early-stage startups, often serving as the first institutional investor for many high-growth companies. Neo focuses on industries like AI, consumer internet, and education, investing in startups that have the potential to drive significant innovation. Neo’s investment strategy is centered on a hands-on approach, offering both financial backing and access to a powerful network of industry leaders. With check sizes ranging from $100K to $5 million, Neo supports startups from seed through Series A stages. They also place a high value on mentorship, connecting founders with an elite community of experienced entrepreneurs, engineers, and executives who offer guidance throughout the startup journey. The firm's portfolio includes some of the most promising startups in the tech space, such as Gusto, Pachama, and Notion. Neo prides itself on fostering diversity and inclusion, believing that the best tech companies are built by teams from a variety of backgrounds. Led by Ali Partovi and supported by a team of seasoned investors and operators, Neo is committed to making a long-term impact in the startup ecosystem by focusing on companies that combine technological innovation with meaningful social impact.

Neo Kuma Ventures, established in 2020 and headquartered in London, is Europe’s largest VC fund focused exclusively on psychedelic healthcare. Neo Kuma aims to revolutionize the treatment of mental health conditions such as depression, PTSD, addiction, and chronic pain through investments in cutting-edge psychedelic therapies. They invest in early-stage companies (Pre-Seed to Series A), deploying capital in the range of £150k to £1 million, with a particular focus on clinical research and digital therapeutics. Neo Kuma's portfolio includes significant players in the field, such as ATAI Life Sciences, Beckley Psytech, and Small Pharma, companies that are advancing the frontiers of mind-altering medicines and therapeutic platforms. Neo Kuma’s strategy is hands-on, working closely with founders to navigate both scientific development and regulatory challenges in this emerging market. The firm is led by a team of experienced investors like Clara Burtenshaw and Sean McLintock, both of whom bring a wealth of expertise in biotech, venture capital, and finance. Neo Kuma is not only a financial backer but also a policy influencer, collaborating with leading organizations in psychedelic research, such as the International Therapeutic Psilocybin Rescheduling Initiative. This integrated approach positions Neo Kuma as a key player in reshaping the future of mental healthcare through psychedelics.

Neoteq Ventures is an early-stage venture capital firm founded in 2020 and headquartered in Cologne, Germany, with a regional focus on the Rhineland. The firm was co-founded by Founding Partners B.J. Park and Simon Schneider, supported by a team of six that includes Clara Bergedieck as Platform Manager, Marie Hildebrand as Investment Analyst, and Jan Jeske as Investment Manager. Neoteq's mission is to support exceptional founding teams from the very beginning — investing from pre-seed through Series A into companies that can solve a relevant customer problem with a technology-led product and have the potential to become market leaders, regardless of industry. Neoteq leads rounds and writes checks of EUR 500,000 to EUR 3 million across AI and software, biotech, B2B SaaS, cleantech, and enterprise applications. The firm has invested in approximately 12 companies, with 4 new investments in the trailing 12 months as of late 2025. It demonstrably leads: the firm led Detechgene's EUR 3.2 million second seed round in August 2025, backing the biotech's 'PCR to Go' mobile molecular diagnostics platform, and led OMMM's seed round of approximately EUR 3.6 to 4.2 million for its AI planning software. NRW.Bank is a frequent co-investor, sharing three deals with Neoteq and underscoring the firm's deep integration with the North Rhine-Westphalian startup ecosystem. Neoteq emphasises long-term partnership over transactional investing, working alongside founders on product development, market entry, and team building from the earliest stages. The firm's Rhineland focus and proximity to Cologne's corporate industrial base gives it a distinctive sourcing advantage for B2B and deep-tech ventures emerging outside Germany's better-known startup hubs.

Neotribe Ventures, founded in 2017 and based in Menlo Park, California, is a venture capital firm that focuses on investing in breakthrough technologies across various sectors including applied artificial intelligence, biotech, enterprise infrastructure, and the internet of things. The firm targets early to growth-stage companies that are shaping the future through innovative solutions. Neotribe Ventures has made 98 investments with notable companies in its portfolio such as Energy Vault, Heliogen, and CipherTrace. The firm has achieved 17 exits, including significant companies like Robinhood, which went public in July 2021. Other successful exits include Pluribus Networks and ClearMotion. The firm is led by co-founders Swaroop Kolluri and Steven Bragonier, along with partners like Nitin Chopra and Neeraj Hablani. Neotribe Ventures manages nearly $450 million in assets across three funds, including the recent Ignite Fund, which focuses on growth-stage investments. Neotribe Ventures' strategy involves providing not just capital but also extensive support and resources to help their portfolio companies succeed. The firm's emphasis on deep technology and innovative solutions makes it a significant player in the venture capital landscape​.

Neulogy Ventures, established in 2014 and based in Bratislava, Slovakia, is a Luxembourg-regulated venture capital fund. The firm focuses on early-stage tech companies, particularly those operating in Slovakia and the Central and Eastern Europe (CEE) region. Neulogy Ventures manages €65 million in assets, with a diverse portfolio spread across 10 countries. The fund targets investments in sectors like media, cleantech, data analytics, productivity applications, medtech, infrastructure, fintech, security, 3D, e-commerce, and new energy. Neulogy Ventures aims to support mission-driven entrepreneurs with bold ideas that push technological frontiers, particularly those addressing climate change and healthcare challenges. Neulogy Ventures emphasizes a hands-on approach, offering strategic guidance, business development support, and fundraising assistance to its portfolio companies. The firm values long-term partnerships, prioritizing shared values and a collaborative approach over quick exits. Notable companies in Neulogy's portfolio include GA Drilling, GreenWay, and GroupSolver. The team, led by managing partners Christian Mandl and Jaroslav Luptak, brings extensive experience in entrepreneurship, fundraising, and business development, ensuring robust support for their investees.

NeuroVentures Capital is a venture capital firm founded in 2000 and based in Charlottesville, Virginia, that claims to be the largest fund in the United States focused exclusively on the neuroscience space. The firm invests in companies developing drugs, medical devices, therapeutics, and technologies to treat central nervous system disorders including stroke, chronic pain, epilepsy, Parkinson's disease, and depression. NeuroVentures manages approximately $15 million and writes tickets ranging from $200,000 to $2 million, backing both development-stage and later-stage companies at seed, Series A, and Series B. The firm is led by Managing Director Mark Cochran, a PhD molecular biologist from Queen's University with postdoctoral training at the NIH, who previously served as VP of Business Development at Bayer Pharmaceuticals, founded MicroGeneSys Inc., and ran the San Francisco office of Toronto-based MDS Capital Corp. He is joined by Director Daniel O'Connell, who has operated multiple medical and healthcare startups. The firm's scientific advisory board includes Floyd Bloom of Scripps Research, Zach Hall (former director of NIH's National Institute of Neurological Disorders and Stroke), William Mobley of Stanford Neurology, and Donald Price of Johns Hopkins. NeuroVentures has made approximately 27 investments with four exits: one IPO — Acumen Pharmaceuticals, listed in July 2021 — and three acquisitions including Concentric Medical and Saegis Pharma. Other notable portfolio names include BrainCells Inc., which raised a $17.7 million Series A in 2005, EnVivo Pharmaceuticals, and Kadmus Pharmaceuticals. NeuroVentures Capital's singular focus on CNS diseases gives it scientific credibility and a curated network of neurologists, pharmacologists, and device engineers that few generalist life-science funds can replicate.

Neva SGR, founded in 2020, is the venture capital arm of Intesa Sanpaolo Group, one of Italy's largest banking institutions. Based in Turin, Neva focuses on investing in technology-driven companies at various stages, from seed to Series C. The firm is sector-agnostic but leans heavily towards fintech, deeptech, ESG transition technologies, and core tech innovations. With two main funds—Neva First and Neva First Italia—the firm targets both Italian and international startups. Neva First focuses on global opportunities, with a minimum of 30% invested in Italian companies, while Neva First Italia co-invests with a more localized emphasis on Italian startups. The funds have a combined budget of around €500 million, with an average ticket size of €4-10 million per investment. Neva SGR is particularly active in life sciences and deeptech, with notable portfolio companies including D-Orbit in space logistics and Tr1X, a biotech firm focused on autoimmune therapies. The firm’s mission is to foster innovation that addresses global challenges while boosting the Italian and European tech ecosystems.

New Enterprise Associates (NEA) is a global venture capital firm with a storied history of supporting innovative businesses. Founded in 1977, NEA manages over $25 billion in assets and invests across all stages of a company's lifecycle, from seed stage to IPO. The firm has a diverse portfolio that spans technology and healthcare sectors. NEA's notable investments include companies like 23andMe, Coursera, Robinhood, and Uber, highlighting their focus on transformational businesses. They have facilitated over 270 IPOs and more than 450 mergers and acquisitions, underscoring their impact on the market. The firm operates from key locations in Menlo Park, California, and New York City, but their investment reach is global, covering North America, Europe, Asia, and beyond. NEA's strategy involves not just funding but also actively mentoring and supporting their portfolio companies through various stages of growth. Recently, NEA closed on two new funds totaling $6.2 billion, the largest in the firm's history, aimed at early-stage and growth-stage investments in sectors like enterprise tech, fintech, digital health, and life sciences. This reflects NEA’s commitment to driving innovation and supporting founders with the capital and expertise needed to build successful companies.

NLV Partners, founded in 2005, is a leading venture capital firm focused on revolutionizing healthcare. With notable investments in companies like CRISPR Therapeutics, Akili Interactive Labs, and iRhythm Technologies, NLV Partners targets biopharmaceuticals, diagnostics, medical devices, and healthcare IT. Their portfolio boasts 30 billion-dollar companies and numerous successful exits, reflecting their impact in the industry. Geographically, NLV Partners concentrates on the United States, partnering with businesses from startup stages to public offerings. Their investment strategy involves backing visionary teams and disruptive healthcare technologies. They aim to develop commercially attractive and clinically important healthcare solutions, leveraging decades of experience and deep domain expertise to navigate the complex healthcare landscape. NLV Partners typically leads investment rounds, providing not only capital but also strategic guidance. They prefer to be approached through well-prepared pitches that clearly demonstrate the potential for clinical and commercial success. The fund's average check size varies, tailored to the needs of each investment. The team includes co-founders Ron Hunt and Vijay Lathi, based in New York and Menlo Park respectively. Both bring extensive experience in healthcare investments and have been instrumental in shaping the firm's strategic direction. For startups seeking a partner with profound industry knowledge and a track record of success, NLV Partners stands out as a pivotal ally in the healthcare sector.

VisVires New Protein, recently rebranded as Clay Capital, is a Singapore-based venture capital firm dedicated to transformative investments in the agrifood tech sector. Founded in 2014, Clay Capital focuses on supporting innovative startups that address fundamental challenges in the food system, particularly in the areas of sustainable packaging, fermentation, agricultural biologicals, crop disease resistance, soil health, and regenerative agriculture. Notable investments include French biostimulant producer Toopi, Israeli bioherbicide startup WeedOUT, and French kitchen robot manufacturer Cook-e. These investments reflect Clay Capital's commitment to leveraging technology to improve sustainability and efficiency in the food and agriculture sectors. Clay Capital's strategy involves investing in early-stage to growth-stage startups, typically with initial checks ranging from $3 million to $8 million, and reserving additional capital for follow-on investments. The firm serves as a bridge between the Asian and European markets, providing startups with support to access and expand in these regions. The rebranding from VisVires New Protein to Clay Capital signifies a renewed focus on building a healthy and sustainable food system, symbolizing fertile ground for growth and innovation. With a newly raised $145 million fund, Clay Capital is well-positioned to continue driving impactful changes in the agrifood tech landscape

New Science Ventures (NSV) is a premier venture capital firm established in 2004, with offices in New York and London. The firm specializes in investing in companies that leverage groundbreaking scientific innovations in the life sciences and information technology sectors. NSV has a keen focus on businesses with strong IP protection and those addressing significant unmet market needs. Notable investments include Ventyx Biosciences, Phase Four, Achronix Semiconductor, and Paragraf. NSV is particularly interested in companies that can transform their industries with innovative scientific approaches. Their strategy is to invest in both early and mid-stage companies, supporting them through crucial growth phases to maximize their potential and value. NSV is not afraid to take contrarian views and often seeks opportunities outside traditional tech hubs, emphasizing the importance of science-based innovation. The firm typically leads funding rounds and provides substantial follow-on support, ensuring that their portfolio companies have the resources needed to succeed. Key team members include co-founder Tom Lavin, who brings over 30 years of experience in finance and investment banking, and Raju Mohan, a seasoned biotech entrepreneur and senior advisor with extensive expertise in drug discovery and development. Startups looking to engage with NSV should emphasize their scientific uniqueness and potential for significant market impact. NSV values strong management teams and clear, defensible IP strategies, making these essential points of focus when approaching the firm.

NewSpring Capital, founded in 1999 and headquartered in Radnor, Pennsylvania, is a private equity firm focusing on growth equity, mezzanine capital, healthcare, and buyouts. The firm manages approximately $3.5 billion in assets and has invested in over 250 companies across various sectors. Notable investments in NewSpring's portfolio include Vacasa, a leading vacation rental management company; Innovid, a video marketing platform; and Nutrisystem, a weight management company. These investments reflect NewSpring's strategy of supporting high-growth companies in business services, healthcare, information technology, and consumer products. NewSpring Capital operates through multiple strategies, including NewSpring Growth, which targets high-growth technology companies; NewSpring Healthcare, focusing on innovative healthcare services and technology; and NewSpring Mezzanine, providing capital for acquisitions and recapitalizations. The firm's comprehensive approach allows them to support companies at different stages of their lifecycle, from early growth to expansion.

New Stack Ventures is an early-stage venture capital firm focused on investing in founders who are often overlooked by traditional venture capital firms. Founded by Nick Moran, New Stack Ventures targets startups in under-capitalized markets and geographies, with a particular focus on IoT, deep tech, smart hardware, and various platform-based business models. The firm recently closed its second fund, New Stack Ventures Fund II, at $42.6 million, significantly larger than its first $6 million fund. This new fund allows New Stack to support an additional 35 companies at the pre-seed and seed stages. The firm prides itself on being one of the largest single-partner funds raised outside of the typical Silicon Valley ecosystem, emphasizing its commitment to backing "outsider" founders. New Stack Ventures has built a strong reputation for its proactive and founder-friendly approach. The firm was highlighted by TechCrunch as one of the most active and engaged investors in the industry. Its portfolio includes notable companies like Draftbit, Curv, and Flamingo, reflecting its diverse investment strategy. The team at New Stack Ventures is comprised of experienced professionals, including Nate Pierotti, Luke Skertich, and Ariella Frank, who bring extensive backgrounds in startups, product management, and venture capital. Their collaborative and inclusive investment process ensures they identify and support high-potential startups effectively.

New York Angels, founded in 2004, is one of the most active and well-established angel investor groups based in New York City. Specializing in early-stage investments, the group has made over 386 investments, with notable successes including Greenhouse Software, Payoneer, and Billtrust. Their portfolio spans various sectors such as Artificial Intelligence, Fintech, Healthcare, and SaaS. New York Angels typically invests in increments starting from $25,000 and expects its members to invest a minimum of $50,000 annually in its deals. Their average investment round size is around $2 million, and they are known for both leading and participating in follow-on rounds. The group has achieved 72 exits, indicating a strong track record of identifying and nurturing high-potential startups. The investment strategy of New York Angels emphasizes thorough due diligence and a collaborative approach, leveraging the diverse expertise of its members. They actively engage with their portfolio companies, providing not only capital but also valuable mentorship and networking opportunities. Key figures in the organization include founder David S. Rose, who has played a pivotal role in shaping the group's investment philosophy and operations. Startups looking to secure funding from New York Angels should be prepared to demonstrate strong business fundamentals and a clear growth trajectory

Empire State Development (ESD) is New York State's chief economic development agency, focusing on promoting business growth, job creation, and enhancing the state’s overall economy. Through various programs and initiatives, ESD supports businesses of all sizes and industries, providing financial incentives, grants, loans, and other resources to foster economic development across the state. One of ESD's flagship programs is the "FAST NY" initiative, which aims to create shovel-ready sites for industrial development, providing substantial grants to improve infrastructure like transportation, utilities, and site development. This program has committed over $175 million to support over 2,700 acres of industrial property. ESD is also a major player in fostering innovation through investments in life sciences and biotech. For instance, the expansion of Harlem Biospace, supported by a $1.5 million ESD grant, exemplifies its role in nurturing New York’s biotech ecosystem by providing advanced facilities for startups and fostering collaboration between businesses and academic institutions like Columbia University. Overall, ESD’s initiatives are focused on strategic job creation, attracting innovative industries, and revitalizing communities, helping to position New York as a competitive environment for both startups and established businesses.

Newfund Capital, founded in 2008, is an entrepreneurial venture capital firm with a strong presence in both Paris and Silicon Valley. With $300 million in assets under management, Newfund focuses on seed-stage startups driving global change. Notable investments include Aircall, Fairmoney, and In2Bones, showcasing their diverse and impactful portfolio. The firm invests primarily in technology, precision medicine, personalized treatment, and brain tech sectors. They emphasize early-stage investments, aiming to support startups from the seed stage through international expansion, particularly in France and North America. Newfund's strategy involves quick decision-making, often providing term sheets within three weeks. They seek entrepreneurs with a global mindset and provide significant value beyond capital, including scaling opportunities, networking, and strategic support. The average check size varies but is tailored to meet the needs of each startup, with Newfund often leading the investment rounds. The team includes key members like Henri Deshays and Patrick Malka, who bring extensive entrepreneurial and investment experience. The team is split between their Paris and Palo Alto offices, allowing them to maintain a strong presence in both Europe and the U.S. For startups looking to scale rapidly with a partner who understands the entrepreneurial journey, Newfund Capital offers a compelling blend of expertise, resources, and strategic guidance.

Newgen Venture Partners is a global angel and seed fund platform founded in 2012 and headquartered in Shanghai, China, with additional offices in Beijing, Hong Kong, and Palo Alto. The firm backs entrepreneurs working in life science and information technology with the most innovative ideas and disruptive technologies, explicitly targeting world-class management and technical teams pursuing disruptive opportunities across TMT, life science, and emerging technology. Newgen is led by Founder and Managing Partner Lu Zhang, who has built the firm into a portfolio of more than 100 companies with accumulated valuations exceeding RMB 50 billion (approximately $7 billion). Newgen leads rounds and is often the first institutional investor in its portfolio companies, writing early seed checks of $100,000 to $3 million. Notable portfolio companies include GrubMarket, a US online grocery and food supply-chain platform that received Newgen's first check at seed in January 2015 and most recently raised a $50 million Series H at a $4.5 billion pre-money valuation in February 2026; HotMaxx, a Chinese food and fast-moving-consumer-goods discount retailer; LePure, a Chinese biotech; and WePie. Portfolio exits include Kheiron Medical Technologies, an AI radiology company acquired by DeepHealth in October 2024, and Paperspace, a cloud GPU infrastructure company. In 2025 to 2026, Newgen led the undisclosed Series A of TuCodec alongside Angel Bay Ventures and MFund. Beyond direct investing, Newgen Capital operates as a limited-partner arm, backing emerging VC funds such as ZPARK Venture and GSR Ventures vehicles, positioning the firm as a platform that accelerates the broader early-stage ecosystem rather than purely deploying direct capital.

Newpath Partners is a Boston-based venture capital firm specializing in life sciences. Founded in 2018 by Dr. Thomas Cahill, Newpath focuses on building biotechnology companies from the ground up, partnering with leading academic scientists to translate groundbreaking scientific discoveries into transformative therapies. With a strong commitment to high-impact ventures, the firm is particularly known for its deep involvement in the early stages of company formation, often acting as a founding investor. Newpath Partners manages multiple funds, with its second fund, raised in 2021, amounting to $350 million. This fund continues Newpath’s mission to back companies with high scientific originality and ambitious goals, particularly in areas like regenerative medicine, genomics, and oncology. The firm typically invests in early-stage ventures, providing not only capital but also strategic guidance and access to a network of industry leaders. Dr. Cahill, who also founded the nonprofit Scientists to Stop COVID-19, leads a team that is highly experienced in both science and business, ensuring that the companies they back are well-positioned to make a significant impact in the life sciences arena. Newpath’s approach is characterized by a close collaboration with founders, aligning interests across scientists, investors, and management teams to drive innovation and success.

Newton Biocapital is a Brussels-based venture capital firm with a strong presence in both Europe and Japan, focusing exclusively on the life sciences sector. Established in 2017, the firm’s investment strategy is centered on supporting companies that tackle chronic diseases, with an emphasis on oncology, metabolic diseases, and neurological conditions. Newton Biocapital plays a hands-on role in its portfolio companies, often leading funding rounds and taking board positions to guide scientific and clinical strategies​. The firm manages two funds—Newton Biocapital I (€114M) and Newton Biocapital II, which is currently targeting €150M. NBC I invested in 14 companies across Europe and Japan, including university spin-offs like Epics Therapeutics and ChromaCure in Belgium, and biotech firms like EditForce in Japan. Newton's approach is deeply integrated with the local ecosystems in both regions, leveraging their strong ties to academic institutions, industry experts, and international investors to facilitate cross-border growth and exits​. Newton’s team combines scientific, regulatory, and investment expertise, led by CEO Alain Parthoens. With offices in Brussels and Tokyo, they are uniquely positioned to bridge the innovation pipeline between Europe and Japan, driving impactful advancements in life sciences​.

NewTribe Capital is a Dubai-based venture capital firm primarily investing in early-stage Web3, blockchain, and AI startups. With a portfolio exceeding 200 projects globally, including sectors like DeFi, gaming, infrastructure, and NFTs, NewTribe actively fosters innovation in the digital space. Some notable investments include Cookie3 and KIP, with an average check size around $200,000. The firm focuses on building long-term partnerships, often providing advisory services such as market-making, growth hacking, and smart contract auditing, to ensure the success of its portfolio companies​. Geographically, NewTribe targets the MENA region, but also extends investments into Europe, Asia, and beyond. Its strategy emphasizes infrastructure development that bridges Web2 and Web3, alongside token-based and equity investments. Notably, NewTribe backs projects aligning with Dubai’s Web3 initiatives, offering support through accelerator programs and partnerships. Led by partners such as Dhaval Parikh and Juliet Su, NewTribe’s team combines technical expertise with deep industry connections. For startups seeking funding, NewTribe looks for founders with strong visions in blockchain or AI, particularly those aiming to create large-scale digital infrastructure.

Next 10 Ventures, founded in 2018 by former YouTube executive Ben Grubbs, is a venture firm dedicated to the global creator economy. Headquartered in Los Angeles and Singapore, the firm focuses on early-stage investments and incubation of businesses within the digital content space. With a $50 million fund, Next 10 Ventures supports startups that offer tools and services for content creators, such as GoMeta, which helps design interactive experiences, and SuperBam, a digital rights management firm. The firm’s average investments range from $250,000 to $500,000. Next 10 Ventures specializes in creator-driven businesses in areas like education, entertainment, and entrepreneurial ventures. Their investment strategy targets creators looking for long-term growth, avoiding short-term "money-grab" opportunities. The firm also provides substantial operational support, including crafting business models for creators, many of whom lack formal plans. The team, including hires like Lauren Schnipper, formerly of Facebook, is spread across key creative hubs like Los Angeles and Singapore, with plans to scale in regions with high creator activity. The firm looks for creators who fit into categories such as artists, entrepreneurs, and educators, while prioritizing sustainability and community impact​.

Next Frontier Capital, founded in 2015 and headquartered in Bozeman, Montana, is an early-stage venture capital firm that partners with mission-driven entrepreneurs in the Rocky Mountain region. The firm focuses on investments in B2B technology and deep tech companies at the Seed and Series A stages. They manage four funds, with the latest being Fund IV, and typically invest between $2 to $10 million per round​. Next Frontier Capital emphasizes supporting the underserved Rocky Mountain startup ecosystem. Their portfolio includes companies like Submittable, Bridger Photonics, and Claravine, reflecting their commitment to high-impact technology ventures​​. The firm values diversity, intellectual rigor, and a strong connection to the region, aiming to create long-lasting companies that contribute significantly to their communities​. The team at Next Frontier Capital, led by founders Will Price and Richard Harjes, brings extensive experience from both venture capital and operational roles. They provide hands-on support to their portfolio companies, leveraging their network and expertise to help founders succeed.

Credit Suisse Entrepreneur Capital Ltd., established in 2010, is the venture capital arm of Credit Suisse based in Zurich, Switzerland. The firm focuses on investing in innovative small and medium-sized enterprises (SMEs) and startups across various sectors, including robotics, automation, medtech, and fintech. To date, Credit Suisse Entrepreneur Capital has invested around CHF 130 million in over 50 companies, and recently expanded its fund by an additional CHF 70 million, bringing the total to CHF 200 million. Notable investments from Credit Suisse Entrepreneur Capital include Perspective Robotics (d.b.a. Fotokite), a Zurich-based startup specializing in tethered drones that improve the safety and efficiency of public safety operations, and Ava, a company in the monitoring equipment sector. These investments highlight the firm’s commitment to supporting high-potential technologies and innovative business models. Credit Suisse's venture capital efforts are part of a broader strategy to support Switzerland's entrepreneurial ecosystem, ensuring the country remains a global leader in innovation and business. For more information about their investments and strategic approach, you can visit their official website.

Next47, the global venture capital arm of Siemens, focuses on investing in early and expansion-stage enterprise tech startups. With a presence in Palo Alto, Berlin, Tel Aviv, London, Munich, and Paris, Next47 specializes in sectors like SaaS, AI, and enterprise technology. Their portfolio boasts notable companies such as Verkada, Skydio, and ChargePoint, reflecting their expertise in backing high-potential tech ventures. Next47's investment strategy emphasizes deep engagement with portfolio companies, providing strategic advice, connections, and resources to help them scale. They lead funding rounds with average check sizes varying based on the stage and requirements of the startup. The firm prides itself on a long-term partnership approach, ensuring consistent support through every growth phase. The fund is highly active, with a robust network of 250+ customers across 15 countries, enabling startups to accelerate their go-to-market strategies and secure significant bookings. Founders benefit from Next47's extensive talent network, assisting in making critical hires and developing executive recruiting strategies. Key team members include Lak Ananth, CEO and Managing Partner, and T.J. Rylander, General Partner, both based in Palo Alto. Their combined experience in venture capital and enterprise tech provides invaluable guidance to startups navigating complex growth trajectories. Next47’s global reach and strategic focus make it a vital player in the enterprise tech venture capital landscape, committed to driving innovation and supporting founders in building the next generation of category-leading companies.

NextGen Venture Partners is a unique venture capital firm that leverages a network-driven approach to investing. Founded in 2012 and based in Baltimore, Maryland, the firm collaborates with over 1,800 Venture Partners to support early-stage and growth-stage companies across various industries in the US​. NextGen typically invests between $1 million to $2 million in seed-stage companies and $3 million to $5 million in growth-stage companies that have $10 million+ in revenue. Their network of Venture Partners, consisting of top entrepreneurs and executives, provides startups with valuable connectivity for sales, hiring, and financing introductions, as well as on-demand advice. The firm's leadership team includes Managing Partners Jon Bassett, Ben Bayat, Brett Gibson, and Chris Keller, along with other experienced professionals like Deborah Chu (Principal) and Corinne Smeriglio (Director of Operations)​. This team brings decades of combined experience in investing and building companies.

NFX, founded in 2015 and headquartered in San Francisco, is a venture capital firm that specializes in early-stage investments. The firm is renowned for its focus on network effects, which it believes are crucial for building market-transforming companies. NFX invests in a diverse range of sectors, including AI, biotech, fintech, gaming, enterprise software, marketplaces, and crypto, with a particular focus on Silicon Valley and Israel. Notable investments by NFX include companies like DoorDash, Lyft, Patreon, and Houseparty. The firm has made a total of 577 investments and has seen significant exits such as Similarweb and CircleUp. NFX's unique approach involves deeply understanding and leveraging network effects, which it views as essential for startups to compete effectively in today's market​​. The firm was co-founded by James Currier, Pete Flint, Gigi Levy-Weiss, and Stan Chudnovsky, who bring extensive entrepreneurial and investment experience. NFX supports its portfolio companies through The Guild, an active community of over 200 founders who share KPIs, insights, and access to foster mutual growth and success​. NFX aims to transform how true innovators are funded, providing not just capital but also strategic guidance to help startups build sustainable and disruptive businesses​.

ND Capital, formerly known as NanoDimension, is a venture capital firm established in 2002, headquartered in Woodside, California. The firm focuses on investing in disruptive technologies across the life sciences, physical sciences, and data sciences sectors. Their core belief is that significant breakthroughs will arise from the convergence of these scientific disciplines. The firm is led by founder and CEO Aymeric Sallin, who has been pivotal in steering the company towards successful investments. ND Capital supports early to mid-stage companies, particularly those developing innovative and market-disruptive technologies. Their investment strategy targets companies at the forefront of scientific advancements that hold the potential to create substantial impact. ND Capital's diverse portfolio includes investments in companies like Natron Energy, Tarveda Therapeutics, Selecta Biosciences, and SQZ Biotech. The firm has a strong track record with numerous successful exits, such as the acquisition of Serotiny by Johnson & Johnson and Icosavax's IPO. The team at ND Capital consists of experienced professionals with deep expertise in various scientific and industrial fields. This includes Senior Partner Patrick Aebischer, who has extensive experience in biotechnology and academic leadership, and Partner Eric Moessinger, who focuses on life sciences investments. ND Capital's mission is to back visionary founders and innovative startups that push the boundaries of science and technology, driving forward transformative solutions that address global challenges..

Nimble Ventures, founded in 2012, is a venture capital firm based in San Francisco, California. The firm focuses on early-stage investments, primarily targeting sectors such as technology, healthcare, biotech, fintech, consumer tech, and blockchain. Nimble Ventures invests globally, with notable investments in companies based in the United States and Israel. Prominent companies in their portfolio include Umbra, a developer of SAR micro-satellites for imagery services, and Terradepth, which provides data collection technology for marine tracking systems. Both companies have shown significant growth and innovation within their respective fields. Nimble Ventures typically invests in Seed and Series A stages, supporting startups with high growth potential and innovative solutions. The firm's investment strategy emphasizes identifying and nurturing early-stage companies that have the potential to transform industries through cutting-edge technology and novel approaches. For startups looking to engage with Nimble Ventures, it is important to demonstrate strong technological capabilities and a clear path to market leadership. The firm values innovative solutions that address substantial market needs and have the potential for significant impact. Key team members include John Burbank, a notable investor with a background in managing substantial venture funds, and Nathan Mee, who brings extensive experience in portfolio management and venture capital investments​.

Nina Capital is a specialized venture capital firm based in Barcelona, focusing on early-stage investments in health technology. Founded by Marta Gaia Zanchi, the firm invests across Europe, the United States, Canada, Israel, and Australia. Nina Capital leverages the Biodesign process from Stanford, which emphasizes a need-driven and value-based approach to healthcare innovation. Their investment strategy spans pre-seed to seed stages, with typical investment sizes ranging from €200k to €1.5m​. The firm supports startups that apply advanced data science, engineering innovation, and IT-enabled products to solve healthcare challenges. Notable portfolio companies include QuantHealth, which uses AI to predict patient responses in clinical trials, and Cardiomatics, offering automated ECG interpretation to improve healthcare efficiency​. The core team, led by principals like Anastassiou and Yahel Halamish, combines deep expertise in healthcare, technology, and investment. They are committed to diversity and multidisciplinary collaboration, fostering an inclusive environment that promotes innovative solutions to complex healthcare problems.

Nippon Technology Venture Partners (NTVP) is Japan's first independent, non-bank-affiliated, hands-on venture capital firm, founded in July 1998 by Kazutaka Muraguchi and headquartered in Setagaya-ku, Tokyo. Muraguchi previously spent 14 years at JAFCO, Japan's largest VC firm, and holds a bachelor's degree in economics from Keio University. NTVP has raised 9 venture funds and manages more than 14 billion yen (approximately $160 million) in capital, with most limited partners being successful entrepreneurs and angel investors — a LP base that reinforces the firm's founder-first culture. Two-thirds of the portfolio consists of startup or seed stage companies. The firm leads rounds across early-stage technology investing, concentrating on information technology, life sciences, clean technology, and media and entertainment. NTVP has invested in 44 companies over 25 years, with seven portfolio companies having gone public: DeNA, the Japanese mobile SNS and gaming giant listed on the First Section of the Tokyo Stock Exchange; Infoteria, listed on Mothers; Ishin Group, listed on TSE in March 2024; and Dentas. Three portfolio companies have been acquired. Notable current portfolio companies include JPYC, a Japanese yen-pegged stablecoin platform; Trinity Security Systems; Mathematec; Akib Networks; and Japan CableCast. The most recent recorded investment was in Ishin Group in June 2023. NTVP's hands-on philosophy sets it apart from Japan's bank-affiliated VC community: the firm takes operational roles, contributes strategic guidance, and works directly with management teams at critical inflection points rather than managing relationships from a distance. This approach has produced a track record of exits across two and a half decades of Japanese technology investing.

Nippon Venture Capital (NVCC) was established in 1996 by Japanese business leaders of blue-chip companies and ranks among the largest independent venture capital firms in Japan. Headquartered on the 34th floor of the Marunouchi Building in Chiyoda-ku, Tokyo, NVCC is led by President Shuichi Okuhara. Over roughly 30 years the firm has raised 21 or more funds — including its NVCC No. 9 flagship vehicle and the Osaka University Venture NVCC No. 1 — totaling approximately $700 million (JPY 100 billion) in capital. NVCC has invested in more than 1,000 companies and produced 174 IPOs as of December 2025, making it one of the most prolific IPO generators in Japanese venture. The firm's enterprise partner and shareholder roster spans Japan Inc.: Ushio, OMRON, ORIX, Kaneka, Kikkoman, Suntory Holdings, Shionogi, Sysmex, Daikin, Daiwa Securities, Fast Retailing, FUJIFILM, Mizuho Bank, Nomura Holdings, MUFG, SMBC, and Nippon Life Insurance, among many others. Academic partnerships with Kyoto University, Osaka University, Nagoya University, and others underpin a strong university-spinout pipeline. NVCC leads rounds and invests from seed through Series B in communications, software, systems and devices, life sciences, and environmental technologies. Recent investments include Neusignal Therapeutics (JPY 1.15 billion Series A, January 2025) and Stayway (Series B, July 2024). Recent IPOs include PRONI (December 2025) and AI Robotics, MFS, and Chordia Therapeutics in 2024. NVCC's breadth of corporate shareholders and university relationships gives it unmatched deal flow across Japan's industrial and academic ecosystem, and its multi-decade IPO track record provides LPs with a proven pathway from early-stage investment to public-market liquidity.